Free Trial
NASDAQ:CFRXU

ContraFect (CFRXU) Stock Price, News & Analysis

→ Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad)
Free CFRXU Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis

About ContraFect

ContraFect Corporation (ContraFect ) is a biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. It intends to address drug-resistant infections using its therapeutic product candidates from its lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). Its product candidates are CF-301, a lysin for the treatment of Staph aureus bacteremia, and CF-404, a combination of mAbs for the treatment of life-threatening seasonal and pandemic varieties of influenza. CF-301 and CF-302 are bacteriophage lysins with potent activity against Staph aureus infections.

CFRXU Stock News Headlines

February 28, 2023 | benzinga.com
Why ContraFect (CFRX) Shares Are Getting Hammered
See More Headlines
Receive CFRXU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ContraFect and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:CFRXU
CUSIP
N/A
CIK
N/A
Web
www.contrafect.com
Phone
+1-914-2072300
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
Beginner's Guide to Pot Stock Investing Cover
Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Steven C. Gilman Ph.D. (Age 64)
    Chairman of the Board, Chief Executive Officer
  • Joshua B. Muntner (Age 48)
    Co-Chief Executive Officer, Senior Vice President - Business Development
  • Michael Messinger CPA (Age 42)
    Co-Chief Executive Officer, Vice President - Finance
  • Roger Pomerantz M.D. (Age 60)
    Vice Chairman of the Board
  • Nancy Dong
    Vice President, Controller
  • Cara M. Cassino M.D. (Age 55)
    General Counsel, Secretary, Chief Medical Officer
  • Natalie Bogdanos (Age 46)
    General Counsel and Corporate secratary
  • Sol J. Barer Ph.D. (Age 69)
    Lead Independent Director
  • Lisa R. Ricciardi (Age 57)
    Director
  • Isaac Blech
    Independent Director

This page (NASDAQ:CFRXU) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners
SHOCKING Crypto Leak…
Crypto 101 Media
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
Traders Agency
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
Banyan Hill Publishing
Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!
American Alternative
How to camouflage a factory of 53,000 workers
Stansberry Research
Man Who Predicted 2008: “This Will be Worse.”
Altimetry
Exposed: 10 CENT Crypto to Explode April 20th?
True Market Insiders